Detalhe da pesquisa
1.
Role of KCNK3 Dysfunction in Dasatinib-associated PAH and Endothelial Cell Dysfunction.
Am J Respir Cell Mol Biol
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38546978
2.
Loss of cAbl Tyrosine Kinase in Pulmonary Arterial Hypertension Causes Dysfunction of Vascular Endothelial Cells.
Am J Respir Cell Mol Biol
; 67(2): 215-226, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35550008
3.
Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis.
Br J Clin Pharmacol
; 88(12): 5227-5237, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35679331
4.
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors.
Eur Respir J
; 56(4)2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32527740
5.
Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation.
Eur Respir J
; 56(5)2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32732333
6.
Awareness campaigns of atrial fibrillation as an opportunity for early detection by pharmacists: an international cross-sectional study.
J Thromb Thrombolysis
; 49(4): 606-617, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31782043
7.
Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study.
Eur Respir J
; 53(5)2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30846469
8.
Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.
Eur Respir J
; 50(1)2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28751413
9.
Pulmonary arterial hypertension induced by tyrosine kinase inhibitors.
Curr Opin Pulm Med
; 23(5): 392-397, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28639957
10.
Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models.
Circulation
; 132(9): 834-47, 2015 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26130118
11.
Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge.
Gastroenterology
; 149(6): 1378-1380.e1, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26253303
12.
Investigating the association between ALK receptor tyrosine kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database.
Eur Respir J
; 58(6)2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34588195
13.
Chemotherapy-induced pulmonary hypertension: role of alkylating agents.
Am J Pathol
; 185(2): 356-71, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25497573
14.
Interferon-induced pulmonary hypertension: an update.
Curr Opin Pulm Med
; 22(5): 415-20, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27387101
15.
Pulmonary arterial hypertension in patients treated with interferon.
Eur Respir J
; 44(6): 1627-34, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25323231
16.
N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats.
Respir Res
; 15: 65, 2014 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24929652
17.
Characteristics and outcomes of gemcitabine-associated pulmonary hypertension.
ERJ Open Res
; 10(3)2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38770007
18.
A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents.
Am J Respir Crit Care Med
; 186(7): 666-76, 2012 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22798315
19.
Calcium-channel blockers in pulmonary arterial hypertension.
Handb Exp Pharmacol
; 218: 161-75, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24092340
20.
Pulmonary hypertension associated with diazoxide: the SUR1 paradox.
ERJ Open Res
; 9(6)2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37965230